Impact Biomedical Initiates Quantum, a New Frontier in Pharmaceutical Development

Impact Biomedical, a wholly-owned subsidiary of SGX-listed Singapore eDevelopment, has announced the initiation of Quantum, a research program designed as a solution to the'patent cliff', the impending pharmaceutical threat. A patent cliff looms when patents for blockbuster drugs expire without being replaced with new drugs, and pharmaceutical companies experience an abrupt decrease in revenue, reducing overall pharmaceutical innovation globally, including crucial research into new methods to prevent and treat illnesses. Impact, through their strategic partner Global Research and Discovery Group Sciences (GRDG), has created a solution called Quantum, a new frontier in pharmaceutical development. Quantum is a new class of medicinal chemistry that uses advanced methods to boost efficacy and persistence of natural compounds and existing drugs while maintaining the safety profile of the original molecules. Instead of modifying functional groups, as is typically done presently in drug discovery, this new technique alters the behavior of molecules at the sub-molecular level.